Ipilimumab-induced immune-related renal failure - A case report

Patrick Forde, Kathy Rock, Graham Wilson, Kenneth J. O'Byrne

Research output: Contribution to journalArticle

Abstract

Ipilimumab is a fully human monoclonal antibody targeting cytotoxic T-lymphocyte antigen-4 and has become the first immune checkpoint inhibitor to enter clinical practice, being recently approved for the treatment of metastatic melanoma. Immune toxicity due to ipilimumab causing colitis, hepatitis, dermatitis and hypophysitis is well-described. We report on a case of acute renal failure resolving rapidly with high-dose corticosteroid treatment highlighting the importance of vigilance for rarer immune-related toxicities as clinical experience with ipilimumab grows.

Original languageEnglish (US)
Pages (from-to)4607-4608
Number of pages2
JournalAnticancer Research
Volume32
Issue number10
StatePublished - Oct 2012

Fingerprint

Renal Insufficiency
CTLA-4 Antigen
Dermatitis
Colitis
Acute Kidney Injury
Hepatitis
Melanoma
Adrenal Cortex Hormones
Monoclonal Antibodies
ipilimumab
Hypophysitis

Keywords

  • Ipilimumab
  • Melanoma metastasis
  • Renal failure

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Forde, P., Rock, K., Wilson, G., & O'Byrne, K. J. (2012). Ipilimumab-induced immune-related renal failure - A case report. Anticancer Research, 32(10), 4607-4608.

Ipilimumab-induced immune-related renal failure - A case report. / Forde, Patrick; Rock, Kathy; Wilson, Graham; O'Byrne, Kenneth J.

In: Anticancer Research, Vol. 32, No. 10, 10.2012, p. 4607-4608.

Research output: Contribution to journalArticle

Forde, P, Rock, K, Wilson, G & O'Byrne, KJ 2012, 'Ipilimumab-induced immune-related renal failure - A case report', Anticancer Research, vol. 32, no. 10, pp. 4607-4608.
Forde P, Rock K, Wilson G, O'Byrne KJ. Ipilimumab-induced immune-related renal failure - A case report. Anticancer Research. 2012 Oct;32(10):4607-4608.
Forde, Patrick ; Rock, Kathy ; Wilson, Graham ; O'Byrne, Kenneth J. / Ipilimumab-induced immune-related renal failure - A case report. In: Anticancer Research. 2012 ; Vol. 32, No. 10. pp. 4607-4608.
@article{eb84f9d2c94e43feb930c1727f78734d,
title = "Ipilimumab-induced immune-related renal failure - A case report",
abstract = "Ipilimumab is a fully human monoclonal antibody targeting cytotoxic T-lymphocyte antigen-4 and has become the first immune checkpoint inhibitor to enter clinical practice, being recently approved for the treatment of metastatic melanoma. Immune toxicity due to ipilimumab causing colitis, hepatitis, dermatitis and hypophysitis is well-described. We report on a case of acute renal failure resolving rapidly with high-dose corticosteroid treatment highlighting the importance of vigilance for rarer immune-related toxicities as clinical experience with ipilimumab grows.",
keywords = "Ipilimumab, Melanoma metastasis, Renal failure",
author = "Patrick Forde and Kathy Rock and Graham Wilson and O'Byrne, {Kenneth J.}",
year = "2012",
month = "10",
language = "English (US)",
volume = "32",
pages = "4607--4608",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "10",

}

TY - JOUR

T1 - Ipilimumab-induced immune-related renal failure - A case report

AU - Forde, Patrick

AU - Rock, Kathy

AU - Wilson, Graham

AU - O'Byrne, Kenneth J.

PY - 2012/10

Y1 - 2012/10

N2 - Ipilimumab is a fully human monoclonal antibody targeting cytotoxic T-lymphocyte antigen-4 and has become the first immune checkpoint inhibitor to enter clinical practice, being recently approved for the treatment of metastatic melanoma. Immune toxicity due to ipilimumab causing colitis, hepatitis, dermatitis and hypophysitis is well-described. We report on a case of acute renal failure resolving rapidly with high-dose corticosteroid treatment highlighting the importance of vigilance for rarer immune-related toxicities as clinical experience with ipilimumab grows.

AB - Ipilimumab is a fully human monoclonal antibody targeting cytotoxic T-lymphocyte antigen-4 and has become the first immune checkpoint inhibitor to enter clinical practice, being recently approved for the treatment of metastatic melanoma. Immune toxicity due to ipilimumab causing colitis, hepatitis, dermatitis and hypophysitis is well-described. We report on a case of acute renal failure resolving rapidly with high-dose corticosteroid treatment highlighting the importance of vigilance for rarer immune-related toxicities as clinical experience with ipilimumab grows.

KW - Ipilimumab

KW - Melanoma metastasis

KW - Renal failure

UR - http://www.scopus.com/inward/record.url?scp=84867760126&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867760126&partnerID=8YFLogxK

M3 - Article

C2 - 23060594

AN - SCOPUS:84867760126

VL - 32

SP - 4607

EP - 4608

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 10

ER -